Kornimate/medical-research-clean huggingface dataset:
study of ccnu (lomustine) plus dasatinib in recurrent glioblastoma (gbm)

Conditions: Glioblastoma

Summary: to determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastoma


Eligibility criteria:
inclusion criteria: * patients with histological or cytological proven glioblastoma multiforme * recurrent or progressive disease documented by magnetic resonance imaging (mri) * world health organization (who) performance status 0 - 2 * patient may have been operated for recurrence * for non operated patients, recurrent disease must be at least one bidimensionally measurable target lesion with one diameter of at least 2cm * patients must be on a stable or decreasing dose of corticosteroids for at least 1 week prior to baseline mri exclusion criteria: * patients with histological or cytological proven glioblastoma multiforme * completion of radiotherapy to the brain less than 3 months prior to registration/randomization * prior treatment with high dose radiotherapy, stereotactic radiosurgery or internal radiation therapy * previous or current malignancy at other sites within prior 3 years
evaluation of a shared decision making portal for pediatric asthma

Conditions: Asthma

Summary: this pilot intervention study will test the feasibility and acceptability and explore the outcomes of a primary care-based shared decision making (sdm) electronic medical record (emr)-based portal that provides education, elicits and tracks patients/families' treatment concerns and goals, assesses symptoms and asthma control over time, and provides decision support to clinicians and families.


Eligibility criteria:
inclusion criteria: * parents/legal guardians of children aged 6-12 with persistent asthma, currently receiving chronic maintenance therapy, cared for at a study practice, with consistent access to a computer with an internet connection where they feel comfortable accessing mychart (patient portal) * clinician at study site exclusion criteria: * parents non-english speaking * child's primary care provider at the time of enrollment is a pediatric resident * not meeting inclusion criteria

Keywords: asthma goals shared decision making patient portal electronic medical record
gallium-68 prostate specific membrane antigen pet in diagnosing patients with thyroid cancer

Conditions: Thyroid Gland Carcinoma

Summary: this pilot clinical trial studies how well gallium-68 prostate specific membrane antigen positron emission tomography (pet) work in diagnosing patients with thyroid cancer. diagnostic procedures, such as 68ga-psma pet, may more accurately diagnose thyroid cancer and find out how far the disease has spread.

primary objectives: i. to determine the feasibility and utility of gallium ga 68-labeled psma-11 (68ga-psma) pet imaging in patients with thyroid cancer. secondary objectives: i. to assess the correlation between targeted molecular uptake of 68ga-psma pet in thyroid cancer compared to areas identified as tumor by radioiodine uptake (in well-differentiated cancers) or fludeoxyglucose f-18 (18f-fdg) uptake (in poorly differentiated and/or radioiodine-negative cancers). ii. to determine and compare the sensitivity and specificity of 68ga-psma pet to (18f-fdg) pet and/or radioiodine scintigraphy. tertiary objectives: i. to determine if 68ga-psma pet uptake is related to tumor differentiation and psma staining in tissue pathology when available. ii. to determine the correlation between standardized uptake value maximum (suvmax) of target thyroid cancer lesions on 68ga-psma pet and serum thyroglobulin levels. outline: participants receive 68ga-psma intravenously (iv) over 1-2 minutes and then undergo pet/mri 60 minutes after injection. patients may undergo a second pet/mri 2-6 months after completion of first scan.

Eligibility criteria:
inclusion criteria: * history of thyroid cancer * whole body 18f-fdg pet/computed tomography (ct) or i-131 scintigraphy within the past 90 days of the scheduled 68ga-psma pet demonstrating uptake * creatinine =\< 3.0 mg/dl * ability to understand a written informed consent document, and the willingness to sign it exclusion criteria: * patients who have had active infection within 15 days of study enrollment that may be considered to interfere with 68ga-psma pet imaging by the study investigators * patients who are unable to have placement of intravenous line access * pregnant or breastfeeding women * patients not capable of undergoing a pet/mri study due to weight, claustrophobia, or inability to lie still for the duration of the exam
brain stimulation for mild traumatic brain injury

Conditions: Traumatic Brain Injury; Post-Concussion Symptoms

Summary: the purpose of this study is to determine the early effects of transcranial direct current stimulation (tdcs) in patients with mild traumatic brain injury and persistent post concussion syndrome(ppcs) with cognitive deficits in long term episodic memory and executive function(inhibitory control).

this is a randomized crossover trial of patients with mild tbi (mtbi) sustaining ppcs. it will be recruited twenty adult patients who will receive three sessions of anodal tdcs: left dorsolateral prefrontal cortex, left temporal cortex(with an intensity of 1.5 ma for 20 min) and sham stimulation(intensity of 1.5 ma for 30 seconds only). sessions will be performed with at least 7 days of interval(wash out period) in a randomized order. patients who meet the inclusion criteria will be assessed with a neuropsychological evaluation - battery tests include beck depression scale, hopkins verbal learning(hvlt), stroop test and digit, letters and numbers sequence. a new battery of computerized neuropsychological test will be performed before and immediately after each stimulation(hvlt, wechsler memory scale, inhibitory control test(ict) and block-tapping test.

Eligibility criteria:
inclusion criteria: * history of mild traumatic brain injury on hospital admission * subjective complain of memory and executive function * must be able to sign the informed consent form exclusion criteria: * under or over age limits * no specific complain of memory and executive function * history of major depression(beck inventory\>35) * drug addiction * uncontrolled epilepsy * presence of any metallic prosthesis implant * presence of cochlear implant * not able to sign the informed consent form

Keywords: traumatic brain injury post concussion syndrome transcranial direct current stimulation neuromodulation
clearance and pharmacokinetics of antibiotics in renal replacement therapy

Conditions: Kidney Failure

Summary: this is an observational study that evaluates the dialysis clearance and pharmacokinetics of antibiotics with different protein-bound levels in patients receiving renal replacement therapy. meropenem, vancomycin and ceftriaxone are selected to represent three typical protein-bound levels, and the primary dialysis methods being studied are intermittent hemodialysis(ihd) and hemodiafiltration(hdf). during and after the dialysis, the drug levels in both plasma and spent dialysate are monitored, but no changes are made to therapy. the study will provide detailed information on the characteristics of the removal kinetics of the three antibiotics during dialysis, and evaluate whether the dosing regimens are the most appropriate to achieve therapeutic targets while minimizing the risk of toxicity.

this prospective, single-center observational study is taken to evaluate the dialysis clearance and pharmacokinetics of antibiotics with three different protein-bound levels in patients receiving renal replacement therapy. as is known that the plasma protein binding rate affects the distribution, metabolism and elimination of the drug in the body, and is also an important factor affecting the removal during dialysis, the study selects meropenem, vancomycin and ceftriaxone, of which the protein-bound levels are respectively 2%, 55% and 85%, to represent three typical protein-bound levels. the primary dialysis methods being studied are intermittent hemodialysis(ihd) and hemodiafiltration(hdf). the dialysis pattern, the antibiotic choice and its dosage for each subject are made on clinical grounds. a total of 16 milliliters of blood and 60 milliliters of spent dialysate are collected from each subject for each dialysis pattern. the study will provide detailed information on the characteristics of the removal kinetics of the three antibiotics during dialysis, and evaluate whether the dosing regimens are the most appropriate to achieve therapeutic targets while minimizing the risk of toxicity.

Eligibility criteria:
inclusion criteria: * with age from 18 to 85 years old. * with weight from 50 to 75 kilograms. * requiring dialysis including intermittent hemodialysis(ihd) or hemodiafiltration(hdf). * receiving meropenem, vancomycin or ceftriaxone based on clinical grounds. exclusion criteria: * patient is during pregnant or lactation period. * patient is allergic to meropenem, vancomycin or ceftriaxone. * severe hypoproteinemia (serum total protein\<=45g/l) or severe hypoalbuminemia（serum albumin\<20g/l). * severe liver dysfunction（alt\>200u/l or ast\>200u/l). * the patient himself or his immediate family refuses to sign the informed consent.

Keywords: kidney failure pharmacokinetics antibiotics
a whole-food, plant-based nutrition intervention in women with metastatic breast cancer

Conditions: Metastatic Breast Cancer; Breast Cancer Stage IV

Summary: this research will examine the feasibility of conducting a strict whole-food, plant-based dietary intervention in women with stable metastatic breast cancer currently undergoing conventional treatments. in addition, this research will provide preliminary data on dietary intakes and the effect of plant-based nutrition on numerous outcomes reflecting cancer prognosis and overall health using advanced imaging, various blood biomarkers linked to cancer progression, and numerous symptom questionnaires.


Eligibility criteria:
inclusion criteria: * women with a confirmed diagnosis of metastatic breast cancer with a stable treatment regimen, demonstrated by no changes in primary cancer therapy 6 weeks prior to consent and no anticipated changes in primary cancer therapy in the 4 weeks following consent. * systemic therapy may consist of any conventional treatment including anti-hormonal, cytotoxic, targeted monoclonal antibody or small molecule kinase inhibitors or any combination of the above. women who have previously declined conventional cancer therapy are also eligible provided they meet all other eligibility criteria. * expected to survive for at least 6 months. * eligibility classification for enrollment into the study - t: any; n: any; m:1. * any er/pr/her2 status is eligible. * age \> 18 years. * must be willing to adopt a strict, whole-foods, plant-based diet. * participant must be willing and able to comply with the protocol for the duration of the study including scheduled testing and weekly office visits. * able to speak and read english fluently. exclusion criteria: * inability to tolerate a normal diet. * current use of insulin or sulfonylureas. * active malabsorption syndrome at time of consent (ie. crohn's disease, major bowel resection leading to permanent malabsorption). * current eating disorder. * uncontrolled diarrhea. * plant-based food allergies or intolerances. * recent consumption (in the past 6 months) of a vegan diet. * gfr \< 30 on 2 or more lab tests in the past 90 days. * serum potassium \> 5.3 on 2 or more lab tests in the past 90 days. * major surgery within 2 months of starting study program. * psychiatric disorder that prohibits giving informed consent. * current smoking. * current high risk alcohol use (\> 7 drinks per week). * current illicit substance use. * current warfarin use.
medial plica syndrome of the knee: conservative treatment versus arthroscopic plica resection - a randomized controlled multicenter trial

Conditions: Plica Mediopatellaris

Summary: the purpose of this trial is to evaluate the effect of conservative treatment in comparison to arthroscopic resection of pathological medial plicae of the knee for patients with medial plica syndrome. the investigators expect conservative treatment to be significantly superior to arthroscopic plica resection with regard to symptom remission and return to prior functional level.


Eligibility criteria:
inclusion criteria: * aged over 18 years * history of antermedial knee pain * palpable medial band in clinical examination or medial plica appearence on mri * absence of all of the following diagnoses: osteoarthritis, osteochondritis dissecans, meniscal injury, patella subluxation, pes anserinus bursit, patellofemoral pain syndrome * given declaration of consent * joining a fitness centre for the duration of minimum 3 months at their own expense. exclusion criteria: aged under 18 years * presence of one or more of the following diagnoses: osteoarthritis, osteochondritis dissecans, meniscal injury, patella subluxation, pes anserinus bursit, patellofemoral pain syndrome * prior surgical intervention, infection, fracture or patellar luxation concerning the relevant knee * not willing to join a fitness centre for the duration of minimum 3 months at their own expense
phase ii study of subcutaneous inj. depot of octreotide in patients with acromegaly and neuroendocrine tumours (nets)

Conditions: Acromegaly; Neuroendocrine Tumors

Summary: this is a phase ii, open-label multicentre, randomised study to assess the pk, pd, efficacy, and safety of two dosing regimens of cam2029 in adult patients with acromegaly or a functional, well-differentiated net, with carcinoid symptoms.

this is a phase ii, open-label multicentre, randomised study to assess the pk, pd, efficacy, and safety of two dosing regimens of cam2029 in adult patients with acromegaly or a functional, well-differentiated net, with carcinoid symptoms, treated for at least 2 months with sandostatin lar at doses of 10 mg, 20 mg, or 30 mg before the start of the sandostatin lar last dose assessment phase (day -28).

Eligibility criteria:
inclusion criteria: acromegaly: * male or female patients ≥18 years of age * acromegaly currently treated with sandostatin lar net: * male or female patients ≥18 years of age * functional, well-differentiated (grade 1 or grade 2) net with symptoms of carcinoid syndrome (number of bowel movements and/or flushing) * currently treated with sandostatin lar for symptom control exclusion criteria: acromegaly: * inadequate bone marrow function * abnormal coagulation or chronic treatment with warfarin or coumarin derivates * impaired liver, cardiac and/or renal function * known gallbladder, bile duct disease or pancreatitis * diabetes with poorly controlled blood glucose levels despite adequate therapy * hypothyroidisms not adequately treated net: * poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, pancreatic islet cell carcinoma, insulinoma, glucagonoma, gastrinoma, goblet cell carcinoid, typical and atypical lung carcinoids, large cell neuroendocrine carcinoma and small cell carcinoma * carcinoid syndrome refractory to treatment with conventional doses of somatostatin analogues (ssas) * inadequate bone marrow function * abnormal coagulation or chronic treatment with warfarin or coumarin derivates * impaired liver, cardiac and/or renal function * known gallbladder, bile duct disease or pancreatitis * short-bowel syndrome * diabetics with poorly controlled blood glucose levels despite adequate therapy * hypothyroidism, not adequately treated

Keywords: acromegaly neuroendocrine tumour (net) carcinoid syndrome octreotide sandostatin lar
the effect of mask design on ventilation parameters in copd and ohs patients on long-term home non-invasive ventilation. an experimental study.

Conditions: COPD (Chronic Obstructive Pulmonary Disease); Obesity Hypoventilation Syndrome (OHS)

Summary: chronic obstructive pulmonary disease (copd) and obesity hypoventilation syndrome (ohs) are respiratory conditions that disrupt normal breathing. positive airway pressure, specifically non-invasive ventilation (niv) delivers positive pressures via an interface such as a face mask and has been shown to improve breathing and reduce symptoms in patients with these conditions. regular use of niv can lead to better symptom management, improved quality of life, and reduced use of healthcare resources. however, poor performance of the niv mask and poor comfort can make niv therapy harder to tolerate. this study will assess if a new mask helps to improve the breathing of people on niv and normalize blood gases.

participants are moved to the sleep laboratory for the night where they are provided with beds. * the participants are put on their prescribed airway pressure support with the first randomized mask. * after at least 60 minutes of recording, participants are awakened to switch back to the second mask. they are then allowed to sleep uninterrupted for the rest of the night.

Eligibility criteria:
inclusion criteria: * age over 18 years * prescribed nocturnal niv for copd or ohs * able to complete an overnight sleep study * comfortable to sleep on a standard double bed * capacity to complete informed consent exclusion criteria: * uncontrolled sleep apnea (apnea-hypopnea index (ahi) over 15 events/hour off personal niv device data) * prescribed ipap above 25 cmh2o * allergic to adhesive of the sensors * self-reported cold/flu symptoms
de-implementing opioids for dental extractions

Conditions: Tooth Extraction

Summary: the overarching goal of this project is to de-implement the reliance on opioid analgesics and to implement reliance on non-opioid analgesics to manage postoperative pain following dental extractions. using a prospective, provider-level, 3-arm cluster randomized trial design, the investigators will compare different strategies to reduce the reliance on opioids and increase the use of alternative pain management approaches utilizing information support tools aimed at both providers and their patients.

the primary objective of this project is to de-implement the use of opioid analgesics for the management of postoperative pain following dental extractions and to implement effective alternative pain management. the investigators propose a cluster-randomized trial design in which dental practitioners will be randomly assigned to 1 of 3 conditions involving different implementation strategies. the first condition, standard practice, will serve as a control condition. the second condition will implement a clinical decision support (cds) tool that will extract patient history and interface with the state prescription drug monitoring program to provide personalized recommendations for analgesic prescribing and offer language for discussing optimal, evidence-based non-opioid pain management with dental extraction patients. the third condition will involve an enhanced version of the cds (cds-e) that will also include information regarding optimal, evidence-based, non-opioid pain management delivered directly to the patient both before and following the dental extraction visit. the investigators will examine opioid and non-opioid prescribing data from the electronic health record across study arms as well as other provider- and patient-focused outcomes using mixed methods.

Eligibility criteria:
patients inclusion criteria: * have a dental extraction of a permanent teeth performed by an eligible healthpartners provider during the intervention period exclusion criteria: * patients who have opted out of research at healthpartners * meet above age criteria

Keywords: decision support systems, clinical pain management analgesics
two low-level laser irradiation protocols on the rate of canine retraction

Conditions: Malocclusion

Summary: several methods aiming at the acceleration of orthodontic tooth movement have been proposed, including low-level laser therapy (lllt), which showed promising results. however, the frequency of patient recall has been one of its major drawbacks.

a randomized controlled clinical trial will be conducted to address the aim of the study. sixteen patients will be recruited, requiring the therapeutic extraction of the maxillary 1st premolars, with subsequent canine retraction into the extraction space. the sample will be randomly divided into 2 equal groups, each including 8 subjects. in group a, one side of the maxillary arch will randomly receive lllt on days 0, 3, 7, 14, and every 2 weeks thereafter, while in group b, one side will also be randomly chosen to receive lllt every 3 weeks. the contralateral sides of both groups will serve as the controls. the lllt applied will be diode laser emitting infrared radiation at wavelength of 980 nm, in a continuous mode. canine retraction in both groups will be carried out bilaterally using nickel-titanium closed-coil spring, delivering 150 grams of force, and the rate of tooth movement will be checked every 3 weeks, over a period of 3 months. other variables will be also examined including, interleukin-1β level in the gingival crevicular fluid, root resorption, and molar anchorage loss.

Eligibility criteria:
inclusion criteria: * malocclusion requires at least the extraction of maxillary first premolars, followed by canine retraction into the extraction site. * normal shape and structure of the maxillary canines, with no history of root canal treatment. * patients with good oral hygiene, and a healthy periodontal condition. exclusion criteria: * patients who underwent previous orthodontic treatment. * patients currently receiving drug therapy that may affect orthodontic tooth movement, e.g. hormonal therapy and corticosteroids. * patients with chronic diseases that may affect the rate of tooth movement. * pregnancy and lactation
the use of transcranial direct current stimulation (tdcs) to study implicit motor learning on patients with brain injury

Conditions: Traumatic Brain Injury; Stroke

Summary: the purpose of this study is to study motor learning and recovery of patients with brain damage caused by traumatic brain injury or stroke with transcranial direct current stimulation (tdcs). it is hypothesized that anodal tdcs on the lesion side and/or cathodal tdcs on the healthy side of motor cortex could improve the recovery of motor function such as learning.

we aim to apply transcranial direct current stimulation (tdcs) to study the recovery process of motor learning on the patients with brain damage caused by traumatic brain injury or stroke. both anodal and cathodal tdcs will be used to test whether the increase of motor cortical activity by anodal tdcs over lesional side or the decrease of brain activity by cathodal tdcs on healthy side will improve the learning skill (srtt: serial reaction time task). the result could help to understand the mechanism of motor and cognitive recovery after brain damage, and further rationalize the application of non-invasive brain stimulation such as tdcs for patient rehabilitation.

Eligibility criteria:
inclusion criteria: * tbi or stroke patients * with partially preserved fine motor function exclusion criteria: * with metal clips in head or device (e.g. pacemaker) * with active cns drugs
efficacy and safety study of shr117887 in combination with metformin in patients with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: shr117887 is a new dipeptidyl peptidase(dpp)-4 inhibitor. this study aims to evaluate the efficacy and safety of shr117887 in combination therapy with metformin in patients with type 2 diabetes in metformin monotherapy who have inadequate glycemic control


Eligibility criteria:
inclusion criteria: * patients diagnosed with type 2 diabetes mellitus * patients have been treated with metformin for at least 8 weeks and be on a stable dose of at least 1500mg daily prior to the screening visit * hba1c：≥7.5% and ≤11.0% at screeing visit and at the end of run-in period * age:≥20 and ≤70 years * bmi(body mass index):≥20 and ≤35 kg/m2 exclusion criteria: -

Keywords: shr117887, metformin,combination,phaseii